(RTTNews) - Johnson & Johnson (JNJ) on Tuesday reported positive topline results from the Phase 2b JASMINE study of nipocalimab in adults with systemic lupus erythematosus (SLE).
The study met its primary endpoint, with a statistically significant proportion of patients achieving the SLE Responder Index (SRI-4) composite response at Week 24 compared with placebo. Nipocalimab's safety and tolerability were consistent with previous Phase 2 studies, with no new safety signals identified.
Based on these results, J&J said it plans to initiate a Phase 3 program for nipocalimab in SLE.
On Monday, JNJ shares closed at $204.31, down 1.47%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
